Gastrointestinal stromal tumor and its targeted therapeutics.
- Author:
Jheri DUPART
1
;
Wei ZHANG
;
Jonathan C TRENT
Author Information
1. Department of Sarcoma Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Benzamides;
Combined Modality Therapy;
Drug Delivery Systems;
Gastrointestinal Neoplasms;
drug therapy;
genetics;
pathology;
surgery;
Gastrointestinal Stromal Tumors;
drug therapy;
genetics;
pathology;
surgery;
Humans;
Imatinib Mesylate;
Mutation;
Piperazines;
therapeutic use;
Protein Kinase Inhibitors;
therapeutic use;
Proto-Oncogene Proteins c-kit;
genetics;
metabolism;
Pyrimidines;
therapeutic use;
Receptor, Platelet-Derived Growth Factor alpha;
genetics;
metabolism
- From:Chinese Journal of Cancer
2011;30(5):303-314
- CountryChina
- Language:English
-
Abstract:
Over the past 60 years, investigators of basic science, pathology, and clinical medicine have studied gastrointestinal stromal tumor (GIST) and made minor advances in patient care. Recent discoveries have led to an understanding of the biological role of KIT and platelet-derived growth factor receptor-α in GIST and the development of the tyrosine kinase inhibitor imatinib mesylate (Gleevec, formerly STI-571), one of the most exciting examples of targeted therapy to date. The success of targeted therapy in GIST has lead to new developments in our understanding of the medical and surgical management of the disease. Intense study of GIST may lead to new paradigms in the management of cancer.
